Avadel Pharmaceuticals (AVDL) Expected to Announce Quarterly Earnings on Monday

Avadel Pharmaceuticals (NASDAQ:AVDL) is projected to post its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.09 per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:00 PM ET.

Avadel Pharmaceuticals Price Performance

Shares of AVDL opened at $21.39 on Friday. The company’s 50-day moving average is $21.51 and its 200-day moving average is $18.95. Avadel Pharmaceuticals has a fifty-two week low of $6.38 and a fifty-two week high of $23.57.

Analyst Upgrades and Downgrades

AVDL has been the subject of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Avadel Pharmaceuticals in a research report on Monday, December 29th. Wells Fargo & Company increased their target price on Avadel Pharmaceuticals from $20.00 to $22.50 and gave the stock an “equal weight” rating in a research note on Thursday, November 20th. Finally, Zacks Research upgraded Avadel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Avadel Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $20.00.

Institutional Investors Weigh In On Avadel Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of Avadel Pharmaceuticals in the 2nd quarter valued at $65,000. Tower Research Capital LLC TRC lifted its holdings in Avadel Pharmaceuticals by 217.5% in the second quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company’s stock valued at $78,000 after buying an additional 6,025 shares during the period. Prudential Financial Inc. bought a new stake in Avadel Pharmaceuticals during the second quarter valued at $96,000. Dynamic Technology Lab Private Ltd bought a new stake in Avadel Pharmaceuticals during the first quarter valued at $115,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in Avadel Pharmaceuticals during the 3rd quarter worth about $122,000. Institutional investors own 69.19% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc is a global specialty biopharmaceutical company focused on developing and delivering treatments for rare diseases and central nervous system disorders. Headquartered in Dublin, Ireland, with operations in the United States, Avadel’s portfolio centers on sleep disorder therapeutics, including its flagship low-sodium oxybate product, XYWAV, which is approved in the U.S. for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The company is also advancing FT218, a once-nightly formulation of sodium oxybate, currently under regulatory review for narcolepsy management.

Formed through a rebranding of Flamel Technologies in 2016 and a strategic shift toward rare disease drug development, Avadel has built its R&D capabilities around improving patient compliance and reducing daily sodium exposure compared to traditional therapies.